Davis Joseph, Director of Biochemistry at FLOGEN Technologies Inc. (Canada), presented a historic breakthrough at the 5th International Symposium on Frontiers in Molecular Science.

At just 23, Joseph discovered that axon-based deamidation of the 4E-BP2 protein is the key driver of neurodegeneration. This finding, known as Davis Joseph’s Principle, redefines how the brain regulates protein synthesis and unites the causes of Alzheimer’s, Parkinson’s, and related diseases under a single mechanism.

His Unified Theory of Neurodegeneration shows that by restoring deamidation to normal values, multiple diseases long studied as separate can be cured with one approach.

Joseph’s two landmark publications in the International Journal of Molecular Sciences have set world records in readership and been covered by over 1,100 media outlets worldwide. Nobel Laureates have described his work as "Nobel Prize worthy."

Pharmaceutical applications targeting axon-specific deamidation are already underway, with potential to revolutionize medicine and create an industry valued at nearly $1 trillion.

Davis Joseph: Lecture at 5th International Symposium on Frontiers in Molecular Science